Cizzle Biotechnology announces cancer-fighting partnership with Fujirebio Diagnostics.
University of York spin-out Cizzle Biotechnology has given US-based life sciences firm Furjirebio Diagnostics exclusive rights to blood testing patents and technology developed at the University of York which detect early-stage lung cancer. The two firms will work together on a commercially valid blood test with the aim to commercialise the kit for worldwide use.…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
